Among the many emerging therapies being evaluated for the treatment of atherosclerosis with anti-inflammatory actions include drugs targeted at p38 mitogen-activated protein kinase (MAPK), lipoprotein-associated phospholipase A2 (Lp-PLA2) and IL-1β. Here, PLA2G7 is linked to atherosclerosis.